Table 2 Baseline characteristics of included studies
Study | Institution | Study type | Outcomes | Period | No. of patients | Median age (year) | Male/female | Median follow-up (month) |
|---|---|---|---|---|---|---|---|---|
Shiba 2021 [10] | Japan (GHMC) | Prospective | Survival, toxicity | 2011–2019 | 53 | 67 (14–84) | 32/21 | 36.9 (4.4–96.4) |
Mohamad 2018 [11] | Japan (NIRS) | Retrospective | Survival, toxicity | 1996–2014 | 26 | 16 (11–20) | 18/8 | 32.7 (1.2–248) |
Imai 2017 [12] | Japan (NIRS) | retrospective | Survival, toxicity | 2000–2012 | 73 | 57 (17–77) | 31/42 | 49.4 (6.4–146.4) |
Imai 2016 [13] | Japan (NIRS) | retrospective | Survival, toxicity | 1996–2013 | 188 | 66 (26–87) | 128/60 | 62 (6.8–147.5) |
Matsunobu 2012 [14] | Japan (NIRS) | prospective | Survival, toxicity | 1996–2009 | 78 | 41 (11–83) | 49/29 | 24 (2–166) |
Imai 2011 [15] | Japan (NIRS) | retrospective | Survival, toxicity | 1996–2007 | 95 | 66 (30–85) | 68/27 | 42 (13–112) |
Mizoe 2009 [16] | Japan (NIRS) | phase I/II or II | Survival, toxicity | 1995–2007 | 33 | 47 (16–76) | 14/19 | 53 (8–129) |
Mattke 2018 [17] | Germany (HIT) | retrospective | Survival, toxicity | 2009–2014 | 79 | 46 | 32/47 | 43.7 |
Uhl 2014 [18] | Germany (HIT) | retrospective | Survival, toxicity | 1998–2008 | 155 | 48 (15–85) | 76/79 | 72 (12–165) |
Uhl 2014 [19] | Germany (HIT) | retrospective | Survival, toxicity | 1998–2008 | 79 | 45 (16–81) | 39/40 | 91 (3–175) |
Combs 2009 [20] | Germany (HIT) | retrospective | Survival, toxicity | 1997–2007 | 17 | 18 (5–21) | 10/7 | 49 (3–112) |
Wu 2019 [21] | China (SPHIC) | retrospective | Survival, toxicity | 2015–2018 | 21 | 64 (28–82) | 10/11 | 21.8 (7.2–39.2) |